FrancophonIA/ELRC3.0 huggingface dataset:
English: In studies in the treatment and prevention of swine enzootic pneumonia, Econor in feed at a dose of 10 to 12 mg valnemulin per kg bodyweight daily (i.e. 200 mg per kg feed) for up to 4 weeks reduced lung lesions, improved clinical signs and pig growth rates compared to untreated pigs.
Estonian: Sigade ensootilise pneumoonia ravi ja ennetamise uuringutes manustati Econori söödas annuses 1012 mg valnemuliini kehamassi kg kohta (söödas 200 mg/kg), mille tulemusena vähenesid kopsukahjustused ning paranesid kliinilised nähud ja sigade kasvukiirus.
English: Econor can only be obtained with a prescription.
Estonian: Econor on retseptiravim.
English: Why is Econor authorised in the EU?
Estonian: Econori Euroopa Liidus heakskiitmise põhjused
English: What measures are being taken to ensure the safe and effective use of Torisel?
Estonian: Mis meetmed võetakse, et tagada Toriseli ohutu ja efektiivne kasutamine?
English: Torisel received a marketing authorisation valid throughout the EU on 19 November 2007.
Estonian: Torisel on saanud müügiloa, mis kehtib kogu Euroopa Liidus, 19. novembril 2007.
English: The European Medicines Agency decided that Torisel's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Toriseli kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Further information on Torisel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Lisateave Toriseli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is given as an infusion lasting 30 to 60 minutes.
Estonian: Seda manustatakse 30-60 minutit kestva infusioonina.
English: Torisel (temsirolimus)
Estonian: Torisel (temsiroliimus)
English: Other information about Torisel
Estonian: Muu teave Toriseli kohta
English: What is Torisel and what is it used for?
Estonian: Mis on Torisel ja milleks seda kasutatakse?
English: Treatment with Torisel should continue until the medicine is no longer working or causes unacceptable side effects.
Estonian: Ravi Toriseliga tuleb jätkata, kuni ravim enam ei toimi või põhjustab vastuvõetamatuid kõrvalnähte.
English: As for all medicines, data on the use of Torisel are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Toriseli kasutamise kohta pidevat järelevalvet.
English: Further information on the orphan designations can be found on the European Medicines Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (renal cell carcinoma: 6 April 2006, expired November 2017; mantle cell lymphoma: 6 November 2006).
Estonian: Lisateave harvikravimiks nimetatud ravimi kohta on leitav Euroopa Ravimiameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (neerurakk-kartsinoom: 6. aprill 2006, aegus novembris 2017; mantelrakuline lümfoom: 6. november 2006).
English: ‘Advanced' means that the cancer has started to spread;
Estonian: „Kaugelearenenud“ tähendab, et vähk on hakanud levima organismis ka mujale;
English: Some side effects can be managed by interrupting treatment or reducing the dose.
Estonian: Teatud kõrvalnähte saab leevendada ravi katkestamise või annuse vähendamisega.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Torisel have been included in the summary of product characteristics and the package leaflet.
Estonian: Toriseli ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Side effects reported with Torisel are carefully evaluated and any necessary action taken to protect patients.
Estonian: Toriseli kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Patients were treated with 25 mg Torisel, with interferon alfa or with 15 mg Torisel in combination with interferon alfa.
Estonian: Patsiente raviti 25 mg Toriseliga, alfainterferooniga või 15 mg Toriseliga koos alfainterferooniga.
English: What are the risks associated with Torisel?
Estonian: Mis riskid Toriseliga kaasnevad?
English: The main measure of effectiveness was how long patients lived without the disease getting worse.
Estonian: Efektiivsuse põhinäitaja oli progresseerumiseta elumus (kui kaua patsiendid elasid ilma haiguse süvenemiseta).
English: For more information about using Torisel, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Toriseli kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Torisel is used in adults when the lymphoma has come back after previous treatment or if other treatments have not worked.
Estonian: Toriseli kasutatakse täiskasvanud patsientidel, kui lümfoom on pärast varasemat ravi taastunud või kui muud ravimid ei ole mõjunud.
English: Each patient received one of two doses of Torisel or the most appropriate alternative cancer medicines chosen by the investigator.
Estonian: Iga patsient sai ühe või kaks annust Toriseli või uuringu läbiviija valitud sobivaimaid alternatiivseid vähiravimeid.
English: Patients receiving Torisel lived for 4.8 months on average without their disease getting worse compared with 1.9 months in those receiving the alternative treatment.
Estonian: Toriseli saanud patsiendid elasid keskmiselt 4,8 kuud ilma haiguse süvenemiseta, alternatiivset ravi saanud patsientide sama näitaja oli 1,9 kuud.
English: How is Torisel used?
Estonian: Kuidas Toriseli kasutatakse?
English: • mantle cell lymphoma (a cancer of B cells, a type of white blood cell).
Estonian: • mantelrakuline lümfoom (vere teatud valgeliblede B-rakkude vähk).
English: Patients are given an antihistamine injection to prevent an allergic reaction around 30 minutes before each dose of Torisel.
Estonian: Allergilise reaktsiooni ennetamiseks tuleb patsientidele anda 30 minutit enne iga Toriseli annust antihistamiini.
English: Torisel is a medicine used to treat patients with the following types of cancer:
Estonian: Torisel on ravim, mida kasutatakse järgmiste vähivormidega patsientide raviks:
English: These diseases are rare, and Torisel was designated an ‘orphan medicine' (a medicine used in rare diseases) on various dates.
Estonian: Need haigused esinevad harva ja Torisel nimetati harvikravimiks eri haiguste jaoks eri kuupäevadel.
English: Torisel must be given under the supervision of a doctor who has experience in the use of cancer medicines.
Estonian: Ravi Toriseliga peab toimuma vähiravimite kasutamises kogenud arsti järelevalve all.
English: Torisel must not be used in patients with mantle cell lymphoma who have moderate or severe problems with their liver.
Estonian: Toriseli ei soovitata kasutada nendel mantelrakulise lümfoomiga patsientidel, kellel on mõõdukad või rasked maksaprobleemid.
English: The most common side effects with Torisel (which may affect more than 1 in 5 patients) include infections, pneumonia (infection of the lungs), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), decreased appetite, hyperglycaemia (high blood sugar levels), hypercholesterolaemia (high blood cholesterol levels), dysgeusia (taste disturbances), difficulty breathing, nose bleeds, cough, vomiting, stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), rash, pruritus (itching), oedema (swelling), tiredness, weakness, fever and mucosal inflammation (inflammation of moist body surfaces).
Estonian: Toriseli kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on infektsioonid, pneumoonia (kopsupõletik), trombotsütopeenia (vereliistakute vähesus), aneemia (punaliblede vähesus), isutus, hüperglükeemia (vere suur glükoosisisaldus), hüperkolesteroleemia (vere suur kolesteroolisisaldus), düsgeusia (maitsehäired), hingamisraskused, ninaverejooks, köha, oksendamine, stomatiit (suu limaskesta põletik), kõhulahtisus, iiveldus, lööve, kihelus, ödeem (turse), väsimus, nõrkus, palavik ja limaskesta põletik.
English: Torisel contains the active substance temsirolimus.
Estonian: Torisel sisaldab toimeainena temsiroliimust.
English: Since mTOR is involved in the control of cell division, Torisel prevents the division of cancer cells, slowing down the growth and spread of the cancer.
Estonian: See kompleks blokeerib valgu mTOR. Et mTOR piirab rakkude jagunemist, ennetab Torisel vähirakkude jagunemist, aeglustades vähi kasvu ja levikut.
English: For the full list of side effects of Torisel, see the package leaflet.
Estonian: Toriseli kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Patients receiving Torisel alone survived 10.9 months on average compared with 7.3 months in those receiving interferon alfa alone.
Estonian: Üksnes Toriseli saanud patsientide elumus oli keskmiselt 10,9 kuud, üksnes alfainterferooni saanud patsientide sama näitaja oli 7,3 kuud.
English: The most serious side effects of Torisel are allergic (hypersensitivity) reactions, serious reactions that occur during the infusion or soon afterwards, infections, lung disorders including pneumonitis (inflammation of the lungs) and pulmonary embolism (blood clot in the lung), bleeding in the brain, kidney failure, tearing (perforation) of the intestine, complications affecting the healing of wounds, hyperglycaemia (high blood sugar), thrombocytopenia (low levels of platelets), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and hyperlipaemia (high blood levels of a type of fat).
Estonian: Toriseli kõige raskemad kõrvalnähud on ülitundlikkusreaktsioonid (allergilised reaktsioonid), infusiooni ajal või varsti pärast infusiooni tekkivad rasked reaktsioonid, infektsioonid, kopsuprobleemid, sh pneumoniit (kopsupõletik) ja pulmonaarne emboolia (trombid kopsudes), ajuverejooks, neerupuudulikkus, soolerebendid, paranevat haava mõjutavad tüsistused, hüperglükeemia (vere suur glükoosisisaldus), trombotsütopeenia (vereliistakute vähesus), neutropeenia (neutrofiilide vähesus) ja hüperlipideemia (teatud rasva suur sisaldus veres).
English: In advanced renal cell carcinoma, a main study involving 626 patients with poor prognosis found Torisel more effective than interferon alfa (another medicine used in the treatment of cancer) at prolonging patients' survival.
Estonian: Kaugelearenenud neerurakk-kartsinoomi põhiuuringus, milles osales 626 halva prognoosiga patsienti, oli Torisel patsientide elumuse pikendamisel efektiivsem kui alfainterferoon (samuti vähiravis kasutatav ravim).
English: What benefits of Torisel have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Toriseli kasulikkus?
English: Patients receiving the lower dose of Torisel in combination with interferon alfa survived for a similar time (8.4 months) as those taking interferon alfa alone.
Estonian: Toriseli väiksemat annust koos alfainterferooniga saanud patsientide elumus sarnanes (8,4 kuud) üksnes alfainterferooni saanud patsientide omaga.
English: How does Torisel work?
Estonian: Kuidas Torisel toimib?
English: An overview of Torisel and why it is authorised in the EU
Estonian: Ülevaade ravimist Torisel ja ELis müügiloa väljastamise põhjendus
English: Torisel must not be used in people who are hypersensitive (allergic) to temsirolimus, to its metabolites (the substances that it is broken down into) including sirolimus (a medicine used to prevent rejection of transplanted kidneys), to polysorbate 80 or to any of the other ingredients of the medicine.
Estonian: Toriseli ei tohi kasutada patsiendid, kes on temsiroliimuse, selle metaboliitide (ravimi organismis lagunemisel tekkivad ained), sealhulgas siroliimuse (siiratud neeru äratõukereaktsiooni ennetamise ravim), polüsorbaat 80 või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Torisel is available as a concentrate and solvent that are made up into a solution for infusion (drip) into a vein.
Estonian: Toriseli turustatakse infusioonilahuse (veeni tilgutatava lahuse) kontsentraadi ja lahustina.
English: The active substance in Torisel, temsirolimus blocks a protein called ‘mammalian target of rapamycin' (mTOR).
Estonian: Toriseli toimeaine temsiroliimus on vähiravim, mille toime seisneb valgu mTOR (imetajate rapamütsiinisihtvalk) blokeerimises.
English: In mantle cell lymphoma, Torisel was found more effective than alternative cancer medicines (such as gemcitabine or fludarabine) in a main study involving 162 patients whose disease had come back after previous treatment or in whom other treatments had not worked.
Estonian: Mantelrakulise lümfoomi põhiuuringus, milles osales 162 patsienti, kelle haigus oli pärast varasemat ravi taastunud või kellel muu ravi oli ebaõnnestunud, oli Torisel efektiivsem kui alternatiivsed vähiravimid (nt gemtsitabiin või fludarabiin).
English: For mantle cell lymphoma, the recommended dose is 175 mg once a week for three weeks, followed by weekly doses of 75 mg.
Estonian: Neerurakk-kartsinoomi ravis on soovitatav Toriseli annus 25 mg üks kord nädalas, kuid raskete maksaprobleemidega patsientidel, kellel on trombotsüütide sisaldus veres suur, soovitatakse kasutada annust 10 mg. Mantelrakulise lümfoomi ravis on soovitatav annus 175 mg üks kord nädalas kolme nädala jooksul, millele järgneb ravi annusega 75 mg nädalas.
English: In the body, temsirolimus attaches to a protein inside cells to make a ‘complex'.
Estonian: Temsiroliimus seondub organismi rakkudes leiduva valguga, moodustades kompleksi.
English: Why is Torisel authorised in the EU?
Estonian: ELis Toriselile väljastatud müügiloa põhjendus
English: The medicine can only be obtained with a prescription.
Estonian: Torisel on retseptiravim.
English: • advanced renal cell carcinoma (a kidney cancer).
Estonian: • kaugelearenenud (neeruvähiliik).
English: (Invented) name
Estonian: (Väljamõeldu d) nimetus
English: 10 (10x1) vials (multi-pack)
Estonian: 10 (10x1) viaali (hulgipakend)
English: 4 vials + 4 ampoules
Estonian: 4 viaali + 4 ampulli
English: 4 vials
Estonian: 4 viaali
English: 10 (10x 1+1) vials + ampoules (multi-pack)
Estonian: 10 (10x 1+1) viaali + ampulli (hulgipakend)
English: 1 vial + 1 ampoule
Estonian: 1 viaal + 1 ampull
English: Immediate packaging
Estonian: Pakendi suurus
English: Romania Alapis Romania s.r.l.
Estonian: Alapis Romania s.r.l.
English: LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATIONS, APPLICANTS IN THE MEMBER STATES
Estonian: RAVIMI(TE) NIMETUSTE, RAVIMVORMI(DE), TUGEVUS(T)E, MANUSTAMISVIISI(DE), TAOTLEJA(TE), MÜÜGILOA HOIDJA(TE) LOETELU LIIKMESRIIKIDES
English: Bulgaria Alapis Bulgaria Ltd., 29, Atanas Dukov Str. 1407, Sofia,
Estonian: Alapis Bulgaria Ltd., 29, Atanas Dukov Str. 1407, Sofia, Bulgaria
English: Jud.IIfov, 077025, Romania
Estonian: Strada Leordeni nr.13, Bragadiru, Jud.IIfov, 077025, Romania
English: Belgium Alapis S.A., 2 Aftokratoros Nikolaou street, 17671 Athens, Greece
Estonian: Nikolaou street, 17671 Athens,
English: Strength Pharmaceutical Form
Estonian: Tugevus Ravimvorm Manustamistee Sisepakend
English: Javlor vinflunine
Estonian: Javlor vinfluniin
English: It contains the active substance vinflunine (25 mg/l).
Estonian: Ravim sisaldab toimeainena vinfluniini (25 mg/l).
English: The full EPAR for Javlor can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Javlori kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Javlor on 21 September 2009.
Estonian: Euroopa Komisjon andis Javlori müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. septembril
English: It must not be used in patients who have or have had a severe infection within the past two weeks or in patients with a neutrophil count of less than 1,500 per mm for the first administration or less than 1,000/mm3 for subsequent administrations or a platelet count less than 100,000 per mm3.
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on või oli viimase kahe nädala jooksul raske infektsioon, ja patsiendid, kelle neutrofiilide sisaldus on alla 1500/mm esimesel manustamisel või alla 1000/mm3 järgmiste manustamiste ajal või kelle trombotsüütide sisaldus on alla 100 000/mm3.
English: During the study all patients received best supportive care (any medicines or techniques to help patients, but not other anticancer medicines).
Estonian: Uuringu jooksul said kõik patsiendid parimat toetavat ravi (mis tahes muud ravimid ja raviviisid, mis patsienti aitavad, peale teiste vähiravimite).
English: The study also looked separately at the results in eligible patients who fulfilled strict criteria such as having had a worsening of the disease after treatment with a platinum-containing medicine.
Estonian: Uuringus vaadeldi eraldi ka nende patsientide tulemusi, kes vastasid rangetele kriteeriumidele, näiteks haiguse süvenemine pärast ravi plaatinat sisaldava ravimiga.
English: Why has Javlor been approved?
Estonian: Miks Javlor heaks kiideti?
English: However, there was a difference among patients who fulfilled the strict criteria entry requirements for the study.
Estonian: Erinevus ilmnes aga patsientidel, kes vastasid uuringus osalemise rangetele kriteeriumidele.
English: Other information about Javlor
Estonian: Muu teave Javlori kohta
English: The most common side effects with Javlor (seen in more than 1 patient in 10) are neutropenia, leucopenia (low white blood cell counts), anaemia (low red blood cell counts), thrombocytopenia (low platelet count), loss of appetite, constipation, abdominal (stomach) pain, vomiting, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), diarrhoea, alopecia (hair loss), myalgia (muscle pain), asthenia (weakness) or fatigue (tiredness), injection site reaction, fever and weight loss.
Estonian: Javlori kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on neutropeenia, leukopeenia (vere valgeliblede vähesus), aneemia (vere punaliblede vähesus), trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus), isutus, kõhukinnisus, kõhuvalu, oksendamine, iiveldus, stomatiit (suu limaskesta põletik), kõhulahtisus, alopeetsia (juuste väljalangemine), müalgia (lihasevalu), asteenia (nõrkus) või väsimus, süstekoha reaktsioon, palavik ja kehakaalu vähenemine.
English: In this group, those given Javlor lived for 6.9 months compared with 4.3 months for patients who were not given the Javlor.
Estonian: Selles rühmas elasid Javlorit saanud patsiendid 6,9 kuud ja Javlorit mittesaanud patsiendid 4,3 kuud.
English: By attaching to tubulin in cancer cells, vinflunine stops the formation of the skeleton, preventing the division and spread of the cancer cells.
Estonian: Kinnitudes vähirakkudes sisalduvale tubuliinile, takistab vinfluniin rakutoese moodustumist ning hoiab ära vähirakkude jagunemise ja levimise.
English: In one main study of 370 adults with advanced or metastatic transitional cell carcinoma of the urothelial tract, patients who were given Javlor treatment were compared with patients who were not given any anticancer medicine.
Estonian: Ühes põhiuuringus, kus osales 370 uroteeli kaugelearenenud või metastaatilise transitoorrakulise kartsinoomiga täiskasvanut, võrreldi patsiente, kes said ravi Javloriga, patsientidega, kes ei saanud ühtki vähiravimit.
English: All the patients had previously received treatment with a platinum-containing medicine which failed.
Estonian: Kõik patsiendid olid varem saanud ravi plaatinat sisaldava ravimiga, mis ei andnud tulemusi.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Javlor.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is the risk associated with Javlor?
Estonian: Mis riskid Javloriga kaasnevad?
English: For more information about treatment with Javlor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Javloriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The CHMP decided that Javlor's benefits are greater than its risks and recommended that Javlor be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Javlori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The doctor may need to adjust the dose by taking into account the patient's age, liver or kidney function and certain side effects that the patient may be experiencing.
Estonian: Arstil võib olla vaja annust kohandada, võttes arvesse patsiendi vanust, maksa- ja neerutalitlust ja ravimi teatud võimalikke kõrvaltoimeid.
English: The dose of Javlor to be given is based on the patient's body surface area (calculated using height and weight).
Estonian: Manustatav Javlori annus määratakse patsiendi kehapindala alusel (arvutatakse pikkuse ja kaalu järgi).
English: Javlor must not be used in people who are hypersensitive (allergic) to vinflunine or other vinca alkaloids.
Estonian: Javlorit ei tohi kasutada patsiendid, kes on vinfluniini või teiste vinka-alkaloidide suhtes ülitundlikud (allergilised).
English: 20 minutes once every three weeks.
Estonian: Javlorit manustatakse 20 minutit kestva veeniinfusiooniga iga kolme nädala tagant.
English: This is a summary of the European public assessment report (EPAR) for Javlor.
Estonian: See on ravimi Javlor Euroopa avaliku hindamisaruande kokkuvõte.
English: It must also not be used in breastfeeding mothers.
Estonian: Samuti ei tohi ravimit kasutada imetamise ajal.
English: The doctor may also delay or stop doses if the patient experiences certain side effects, including low levels of platelets and neutrophils (a type of white blood cell), and certain side effects affecting the heart, liver or lungs.
Estonian: Arst võib annustamisega viivitada või selle peatada, kui patsiendil ilmnevad teatud kõrvalnähud, sh trombotsüütide ja neutrofiilide (teatud valgeliblede) liiga väike sisaldus, ning südame, maksa või kopsudega seotud teatud kõrvalnähud.
English: The active substance in Javlor, vinflunine, belongs to the group of anticancer medicines known as the vinca alkaloids.
Estonian: Javlori toimeaine vinfluniin kuulub vähiravimite vinka-alkaloidide rühma.
English: The recommended dose is 320 mg per m2. Javlor is given as a drip into a vein over a period of
Estonian: Soovitatav annus on 320 mg/m2.
English: Javlor is used when previous treatment with a platinum-containing anticancer medicine has failed.
Estonian: Javlorit kasutatakse juhul, kui varasem ravi plaatinat sisaldava vähiravimiga ei ole andnud tulemusi.
English: How does Javlor work?
Estonian: Kuidas Javlor toimib?
English: Javlor is a concentrate for solution for infusion (drip into a vein).
Estonian: Javlor on kontsentraat, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: Javlor with best supportive care was more effective than best supportive care alone in prolonging the lives of patients with advanced or metastatic transitional cell carcinoma of the urothelial tract.
Estonian: Javlor koos parima toetava raviga oli uroteeli kaugelearenenud või metastaatilise transitoorrakulise kartsinoomiga patsientide eluea pikendamisel efektiivsem kui üksnes parim toetav ravi.
English: It attaches to a protein in cells called ‘tubulin', which is important in the formation of the internal ‘skeleton' that cells need to assemble when they divide.
Estonian: See kinnitub rakkudes sisalduvale valgule tubuliinile, mis on tähtis rakkude jagunemiseks vajaliku raku sisetoese moodustumisel.